Search hospitals > Virginia > Richmond
Virginia Cancer Institute
Claim this profileRichmond, Virginia 23230
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
174 reported clinical trials
20 medical researchers
Summary
Virginia Cancer Institute is a medical facility located in Richmond, Virginia. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Virginia Cancer Institute is involved with conducting 174 clinical trials across 166 conditions. There are 20 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Khalid Matin.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Andrew Poklepovic, MDVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Expert in Cancer
Expert in Tumors
33 reported clinical trials
82 drugs studied
Sarah W. Gordon, DOVirginia Commonwealth University/Massey Cancer Center8 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
26 reported clinical trials
54 drugs studied
Leslie Randall, MDVCU Massey Cancer Center1 year of reported clinical research
Studies Ovarian Cancer
Studies Cancer
19 reported clinical trials
35 drugs studied
Khalid MatinVirginia Commonwealth University/Massey Cancer Center4 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
13 reported clinical trials
29 drugs studied
Clinical Trials running at Virginia Cancer Institute
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Bile Duct Cancer
Multiple Myeloma
Colorectal Cancer
Rectal Cancer
Solid Tumors
Liposarcoma
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
This trial compares the effectiveness of a combination of two drugs, SG and pembrolizumab, in patients with advanced triple-negative breast cancer. SG targets and kills cancer cells with chemotherapy, while pembrolizumab helps the immune system attack the cancer. Pembrolizumab has been shown to improve survival in various cancers, including triple-negative breast cancer, when used alone or in combination with other treatments.
Recruiting4 awards Phase 3
Gedatolisib + Fulvestrant +/- Palbociclib
for Advanced Breast Cancer
This trial is testing a combination of drugs to treat advanced breast cancer that has not responded to other treatments. The drugs work by blocking growth signals, breaking down estrogen receptors, and stopping cell division. Tamoxifen is a commonly used drug that blocks estrogen receptors to treat breast cancer, but resistance to it often develops.
Recruiting2 awards Phase 311 criteria
sac-TMT + Pembrolizumab
for Breast Cancer
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (sac-TMT; MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sac-TMT plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. It is hypothesized that sac-TMT plus pembrolizumab is superior to TPC with respect to iDFS per investigator assessment.
Recruiting2 awards Phase 35 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Virginia Cancer Institute?
Virginia Cancer Institute is a medical facility located in Richmond, Virginia. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Virginia Cancer Institute is involved with conducting 174 clinical trials across 166 conditions. There are 20 research doctors associated with this hospital, such as Andrew Poklepovic, MD, Sarah W. Gordon, DO, Leslie Randall, MD, and Khalid Matin.